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Abstract: Achieving good long- and short-term adherence to treatment for chronic diseases is 
important if patients are to gain the full benefits of treatment. Several barriers to adherence in 
multiple sclerosis (MS) have been identified and the healthcare team should work with patients to 
help them to overcome these obstacles. The MS Choices survey explored patient and physician 
perspectives on key aspects of MS diagnosis, treatment adherence, and disease management 
with the aim of improving understanding of the factors that influence patient behavior regarding 
treatment adherence. The survey found some important differences between patient and physician 
responses and here these findings are discussed in the context of personal clinical experience. 
Further, the possible implications of these findings for routine practice have been considered, 
and strategies that should be employed by MS physicians and nurses to help patients to adhere 
to their prescribed treatment are suggested.
Keywords: multiple sclerosis, treatment adherence, treatment initiation, patient–physician 
dialog, psychological profiling
Introduction
Among patients with chronic diseases requiring long-term medication, achieving and 
maintaining good adherence to treatment is both critical and problematic.1–3 Many 
fa  ctors can contribute to poor adherence over the long-term, including treatment fatigue, 
forgetfulness, and treatment-related side effects.2,4–6 In patients with multiple sclerosis 
(MS), additional disease-related factors may also contribute to poor adherence. In a 
disease characterized by relapses and periods of remission, patients may think that 
they do not need to take their treatment when they feel well, or they may perceive that 
their treatment is not working in the event of a relapse or simply because symptoms 
persist despite treatment. Perceived lack of efficacy was found to be the main cause 
of treatment discontinuation in a cohort of Italian patients.7
Clinical experience tells us that specific symptoms of MS can also impact on 
adherence; for example, impaired visual function or manual dexterity, or spasticity, 
may affect the patient’s ability to perform injections. Cognitive impairment and 
depression may also make it difficult for the patient to fully understand the importance 
of maintaining a regular treatment pattern, whereas anxiety or loss of memory may 
make it difficult for patients to remember when to take their medication, or may lead 
to confusion over when the last dose was taken. Moreover, with all established first-
line treatments still requiring regular parenteral administration, needle phobia, fear 
of injection, and concerns over the ability to self-inject correctly present significant 
barriers to adherence for many patients with MS.8
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The importance of achieving good treatment adherence is 
clear: poor adherence or breaks in treatment can limit treat-
ment benefits and have a detrimental effect on disease-related 
outcomes, such as axonal damage.9,10 It has been suggested 
that addressing poor adherence has the potential to have a 
greater impact on treatment efficacy than the development 
of new drugs,11 and could also achieve a better cost:benefit 
ratio. From an economic perspective, early and consistent 
treatment should also provide benefits by reducing healthcare 
costs associated with relapses or increased disability.9
It is imperative that adherence is addressed both imme-
diately after treatment initiation and over the longer-term. 
The World Health Organization’s definition of adherence1 
highlights the role of the patient as the key decision maker 
in the treatment process and the driver of treatment success. 
Therefore, the authors believe that it is important to consider 
which factors will motivate patients at different stages of 
their disease. That the motivating factors may differ between 
patients and change over time should also be recognized. 
Patients who are “doing well” or have just started treatment 
must receive the appropriate support to minimize the likeli-
hood that they will take breaks from or permanently discon-
tinue treatment. In addition, the authors have found in their 
clinics that different patients will be more concerned over 
different aspects of treatment, such as efficacy, side effects, 
or convenience. For example, in the authors’ experience, side 
effects, in particular injection-site reactions, are of great con-
cern for some patients such as young women who may find 
their appearance embarrassing. Throughout their treatment, 
patients need to be helped to understand that they may have 
to make some sacrifices now (eg, having to accept “flu-like” 
symptoms, which are common early in treatment but tend 
to abate over time) to achieve better long-term outcomes. 
Through direct contact with patients, the healthcare team 
has the potential to impact patient adherence positively.5 
However, for this to be possible, the authors believe that 
the healthcare team needs accurate information on patients’ 
perceptions of their disease and treatment. A good patient–
physician or patient–nurse relationship, in which patients 
feel comfortable voicing their honest opinions, and a good 
understanding of patients’ needs, wants, and expectations of 
treatment, are also essential.
Several approaches, including the provision of injection 
devices and patient support programs, have been employed with 
the aim of improving the patient’s experience of treatment, and 
thus adherence. Of these, injection devices have the potential to 
help patients to overcome some of the psychological b  arriers 
to self-injection, for example by keeping the needle hidden 
throughout the injection process.12 Whether injection devices 
increase adherence has yet to be confirmed, but a recent obser-
vational study of 1077 patients with MS in 15 countries found 
that use of an injection device was the strongest predictor of 
treatment adherence over 24 months.13 Reductions in the occur-
rence of injection-site reactions and injection-related discomfort 
with injection device use have also been reported.2,14,15
The MS Choices survey was carried out to investigate 
patient and physician perspectives on key aspects of MS 
diagnosis, treatment adherence, and disease management. It 
was hoped that the survey results would improve understand-
ing of the extent of poor adherence and cultural/economic 
influences on treatment initiation and adherence. Results 
of the survey have been published;16 a commentary on this 
paper is provided here, discussing the findings in the context 
of the authors’ personal clinical experience, and suggesting 
the implications of these findings for routine practice.
The MS Choices survey
Background of the survey
The MS Choices survey was conducted in seven co  untries 
(Australia, Canada, France, Germany, Italy, Spain, and 
the UK) across three continents. Patients who had been 
di  agnosed with MS for $1 year and were currently receiving 
disease-modifying drug (DMD) treatment and neurolo-
gists with 3–30 years of clinical experience treating on 
average $15 patients with MS per month were invited to 
participate. Overall, 331 patients and 280 neurologists took 
part. Participation required that two questionnaires (one each 
for patients and physicians) that had previously undergone 
pilot testing were completed; both contained closed- and 
open-answer questions. Patients completed a semi-structured 
paper questionnaire comprising 37 questions (including two 
free-text questions) that took approximately 20 minutes to 
complete. Physicians completed an online questionnaire com-
prising 29 questions (24 closed answers and five percentage 
estimations) that took approximately 15 minutes to complete. 
The questionnaires can be found in the published results of 
the MS Choices survey.16
Summary of results
Several differences were found between patient and physician 
responses, particularly for questions relating to treatment 
adherence. Almost twice as many patients reported taking 
a treatment break as the number estimated by neurologists. 
Differences were also seen between the reasons for poor 
adherence given by patients and physicians. Although both 
groups reported side effects as the main reason for poor 
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adherence, this response was given by almost twice as many 
physicians as patients (82% vs 42%). Whereas 54% of phy-
sicians thought patients would stop treatment because they 
thought it was not working, only 9% of patients cited this 
reason. In addition, 13% of patients reported that they would 
stop treatment as they felt drained or fed up with treatment. 
It is important to consider that a patient’s reasons for feeling 
fed up could include the perception that they were not gaining 
benefit from their treatment.
Differences were also seen between physician and patient 
responses regarding the timing of treatment initiation and 
patient involvement in treatment decisions. Notably, whereas 
47% of physicians thought that patients were fully involved in 
deciding their treatment, only 23% of patients felt that they had 
discussed treatment with their healthcare team and had been 
responsible for their treatment selection. Regional differences 
in responses regarding these practices were also observed.
The authors of the survey concluded that neurologists 
may underestimate the scale of poor adherence to DMDs. 
This conclusion is understandable as 59% of physicians 
did not consider adherence to be a problem, yet a study of 
2648 patients with MS, in which adherence was defined as 
not missing any DMD injection in the 4 weeks before the 
study, reported that one-quarter of patients were not adherent 
to therapy.17,18 As the MS Choices authors noted, assuming 
good adherence could result in a treatment being incorrectly 
considered as ineffective. The concern in such a situation 
is that this may result in unnecessary treatment escalation, 
exposing the patient to the potential risks associated with 
more aggressive treatment. It was also concluded that dis-
parities exist between patients’ and physicians’ opinions 
regarding the reasons for poor adherence, and the authors 
proposed that improving the patient–physician dialog may 
increase adherence to DMDs.
Commentary on the MS Choices 
survey findings
Patients and physicians completing  
the survey
The survey was designed to involve representative patient and 
physician populations in countries with a high pr  evalence of 
MS and good access to treatment. Both patient and ph  ysician 
numbers were distributed evenly across participating 
c  ountries. Neurologists were identified by a specialist pro-
vider and were screened using the eligibility questions before 
completing the questionnaire to ensure that they had substan-
tial and ongoing experience of treating patients with MS. 
All patients had been diagnosed with MS for $1 year 
and were currently taking DMD treatment, ensuring that 
responses related to current practices. As newly diagnosed 
patients were excluded, experiences of those who started 
treatment immediately after diagnosis were not captured.
Although the above requirements ensured that a popula-
tion representative of patients with MS with experience of 
DMD treatment was included in the survey, there were some 
limitations. As there was no upper limit for duration of MS, 
many responses (particularly those relating to treatment ini-
tiation) were reliant on patients’ memory. Considering this, 
it would have been interesting to see how responses differed 
between groups of patients stratified by, for example, time 
from diagnosis or duration of therapy. It would also have been 
interesting to include MS nurses in the survey to see how 
their perceptions of patient experience of treatment differed 
from those of physicians and patients themselves.
Discrepancies between patient  
and physician responses
For all topics explored, discrepancies were found between 
patient and physician responses, as discussed in more detail 
for specific topics below. There are several possible reasons, 
in general, for such discrepancies. Physicians and patients 
were selected independently and not “matched;” therefore, 
these could reflect true differences in treatment practices. 
Questions in the patient and physician questionnaires were 
phrased differently and may have explored different specific 
aspects of the treatment experience. Furthermore, physicians 
probably responded in general terms about their behavior 
at the time of the survey, whereas patients would have 
reported their own personal experience relating to practice 
at the time of their diagnosis, and may depend on imperfect 
recall; therefore, general practices were most likely compared 
with individual cases. For both questionnaires, many ques-
tions included “fixed” answers, which may have prompted 
a particular response. A previous study also revealed differ-
ences in opinion between patients with MS and physicians 
when asked about treatment continuation and the risks 
associated with natalizumab treatment.19
Regional differences in responses
Several differences between countries were identified in the 
MS Choices survey. While the reasons for cultural/regional 
differences were not explored, these could reflect differ-
ent processes within the healthcare system that influence, 
for example, the time at which DMD treatment can occur, 
different access to healthcare or differences in healthcare 
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  funding, and cultural differences such as the desire of patients 
to be involved in decisions regarding their treatment. It is 
important to remember that regional differences can also 
exist within a single country. For example, in some areas of 
Spain, a central committee must approve initiation of DMD 
therapy, incurring delays of 3–6 months until a treatment 
can be started, whereas other regions have no committee, so 
immediate initiation of therapy is possible. Thus, the reasons 
for the observed differences are likely complex.
Lessons from MS Choices
Treatment initiation
Timing of treatment initiation
An interesting finding was the large discrepancy between 
the timing of treatment initiation after diagnosis reported by 
patients and physicians. In general, most physicians reported 
that they treated patients during the first 6 months following 
diagnosis, whereas over a third of patients reported waiting 
more than a year after diagnosis before starting treatment. 
Unfortunately, the duration of treatment was not captured 
in the survey, so it is not known whether this difference 
reflected, for example, changing practices over time or real 
differences owing to patients and physicians not having 
been “matched.”
The time from diagnosis to the start of treatment also 
differed between countries. Most ($80%) physicians in 
Germany and Australia reported starting treatment within 
2 months of diagnosis, while a minority (,40%) from the 
UK and Spain did so. In Italy, Canada, and France, approxi-
mately half of physicians reported starting treatment within 
2 months of diagnosis. This finding may relate to differences 
in the healthcare systems, as noted above.
Delaying the start of treatment
Reasons for delaying treatment initiation were not captured 
in the survey, but should be considered. The physician may 
deliberately delay treatment for some patients, for example, 
to allow time for the patient to accept the MS diagnosis and 
the need for treatment. As a patient’s emotional state can 
influence their ability to accept their situation, the same 
management schedule cannot be applied to all patients. 
Where there is a delay in starting treatment, it is important 
that the reasons for this decision are explained to the patient, 
as improving patient engagement could have a positive effect 
on adherence. Furthermore, a delay in starting treatment 
could suggest that treatment is not very important, which 
could influence a patient’s subsequent attitude to treatment 
and reduce adherence. On the contrary, a short delay might 
be necessary to allow patients to adjust to their diagnosis, 
overcome depression and anxiety, and understand not only 
the importance of treatment but also the possible side effects. 
Considering that patients with MS can experience psycho-
logical distress, even in the early stages of their disease,20 
allowing patients time to come to terms with their situation 
could help to avoid discontinuations in the first 6 months 
of treatment. Preventing early discontinuations may be 
particularly important to achieve good long-term adherence 
and outcomes. A retrospective review of Canadian patients 
with MS receiving interferon-β therapy found that the high-
est proportion of treatment interruptions occurred in the 
first 6 months after starting therapy.4 Crucially, the level of 
information given to a patient at diagnosis regarding treat-
ment and the need for treatment should be tailored to the 
individual as far as possible.
Treatment adherence
Physicians’ and patients’ perspectives on reasons  
for poor treatment adherence
Side effects were the main reason given by both patients (42%) 
and physicians (82%) for poor treatment adherence, although 
clearly physicians considered side effects a more important 
driver of nonadherence than did patients. Other differences 
between patient and physician responses to questions explor-
ing reasons for poor treatment adherence were also seen. From 
the physician’s perspective, the vast majority of patients stop 
treatment for reasons associated with efficacy or side effects. 
In contrast, many patients cited being emotionally drained or 
fed up with treatment, practical issues relating to injecting, or 
forgetfulness. None of these reasons were cited by physicians, 
although physicians might have considered these psychologi-
cal issues to be contributors to “perceived lack of efficacy,” 
and might have considered reasons for nonadherence as a 
balance between the pros and cons of treatment and overall 
impact on patient quality of life.
For many patients, fitting the need to inject around their 
lifestyle was the biggest challenge, and how to help patients 
to overcome this issue should be addressed by their medical 
team. The responses regarding reasons for poor adherence 
suggest that physicians think mostly in terms of the effect 
of treatment on physical symptoms, and not in terms of the 
overall effect that treatment may have on the patient’s life-
style. This finding highlights the need to educate physicians 
about the issues that are important to patients, the importance 
of flexibility in treatment administration, and the need to have 
more discussions with their patients, ideally asking open 
questions about any concerns the patient may have.
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In the authors’ experience, patient expectation of therapy 
is possibly the most important factor predicting adherence: 
those with unrealistic expectations are likely to discontinue 
treatment early, often at the time of first relapse. Periodic 
checks of patient expectations can be conducted using a 
simple questionnaire that the patient completes while wait-
ing to see the neurologist or nurse. Gaining the MS nurse’s 
perspective on the issues that are important to patients would 
have been interesting, since nurses may have been more 
aware than physicians of problems such as being emotionally 
drained by the need for regular injections.
Are scheduled treatment breaks justified?
Differences were also seen in the proportion of patients who 
reported taking a treatment break (31%), which was higher 
than the proportion of patients estimated by physicians 
as having taken a treatment break (17%). This may have 
reflected the different wording of the question in the two 
questionnaires, since “treatment break” was defined in the 
question for patients but not for physicians. The definition 
of treatment break given to patients (not taking treatment for 
“1 day or longer”) is more stringent than that applied in many 
studies, which may be closer to the physicians’ understanding 
of a “treatment break.” The perception of adherence may also 
differ between physicians, with younger physicians more 
open to the issue of poor treatment adherence.
Although .90% of physicians reported having at least 
one patient who had taken a break from or stopped their 
MS therapy, 59% did not think compliance was an issue. 
One explanation could be that physicians authorize treat-
ment breaks and consider patients taking such a break to 
be compliant. Based on the authors’ clinical experience, 
it is estimated that around 2%–15% of patients take an 
authorized treatment break. The MS Choices survey found 
that, overall, ∼17% of patients were thought to have taken 
a treatment break. That the authors’ personal experience is 
consistent with the findings of this survey of a wider group of 
physicians suggests that a significant proportion of patients 
(up to ∼20%) are probably taking breaks in their treatment 
following a discussion of the pros and cons with their 
physician. Authorized treatment breaks may have benefits 
for many patients. A flexible approach to treatment, such 
that patients are permitted to take a short break (eg, during 
vacations), could increase the likelihood that a patient will 
stay on therapy in the longer-term. Permitted flexibility may 
show patients that their physicians understand their desire 
to be free from the burden of treatment for a short period, 
and may thus strengthen the patient–physician relationship. 
An understanding approach fosters open discussion and 
provides the opportunity for physicians to advise patients 
on how to adapt their treatment routine to provide flexibility 
while avoiding missed injections. Furthermore, open discus-
sions allow physicians to explain the risks associated with 
even short-term interruptions, and to remind patients of the 
importance of continuing therapy over the long-term.
Realistically, it is likely that many, if not all, patients 
will at some point choose to miss some injections. In some 
instances, a flexible approach to treatment in the short-term 
may enable the patient to remain on treatment for the long-
term; however, the potential benefits of treatment breaks have 
not been studied. In light of the lack of good-quality trial data 
to inform clinicians’ decisions, it is difficult to advise when 
and in whom treatment breaks may be appropriate. Of course, 
ideally all patients would stay on uninterrupted treatment, but 
both the MS Choices survey and previous studies suggest that 
this is not the reality. Therefore, it is suggested that interrupt-
ing treatment should probably only be considered for patients 
who have had 2–3 years of stable disease, and would caution 
against authorizing a treatment break in patients with evidence 
of disease activity despite treatment. Furthermore, disease 
reactivation has been reported upon stopping treatment after 
only a short treatment period.21 However, readers should be 
reminded that this recommendation is based primarily on 
the authors’ clinical experience, not trial data, and are urged 
to consider each individual case carefully before making a 
decision.
Improving adherence in clinical practice
How to improve adherence is a complex problem, and may 
require several approaches (Table 1). As indicated in the su  rvey, 
adherence is influenced by many variables, including side 
effects, how well the treatment fits with the patient’s li  festyle, 
demands of work and family, and planned pregnancy. The MS 
Choices survey highlighted that patients’ concerns about adher-
ence to their MS therapy differ from the issues that physicians 
Table 1 Strategies to improve adherence to multiple sclerosis 
therapies: patient–physician and patient–nurse interactions
•  Understanding the factors that predict adherence
•  Maintaining good patient–physician or patient–nurse communication
•  Educating patients on the importance of adhering to therapy
•  Educating physicians/nurses regarding issues that are important to patients
•  Identifying patient-specific barriers to adherence
•  Managing adverse events to preserve quality of life
•  Managing patient expectation of therapy and setting realistic goals
•  Identifying and setting manageable treatment schedules
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consider most important. This finding again suggests there is a 
need for physician education regarding the issues that are impor-
tant to patients. The medical team must learn to understand what 
is important to patients, and to talk in terms that are meaningful 
if they hope to influence adherence positively.
Motivating patients to continue treatment
Maintaining adherence over the long-term can be problematic. 
Keeping patients motivated requires a long-term commitment 
from the healthcare team – patients who have been on 
treatment for many years should not be overlooked. Various 
strategies may help to achieve good long-term adherence and 
should be considered (Table 2). Education and maintaining 
motivation need to be regular events; indeed, frequent 
patient–physician/nurse interaction is key to a successful 
outcome. Physicians should ideally be trained in techniques to 
communicate better with and motivate patients, recognizing 
that these techniques will need to be tailored to the individual. 
This might be achieved through residential courses dedicated 
to professionals. A pilot study, based on experience with 
the “Sapere Migliora (knowing improves)” information aid, 
has been performed in Italy with the financial support of the 
Italian MS Society, and demonstrated the benefits to patients 
of providing additional information on their disease in an 
accessible format.22,23
Recording patients’ positive and negative views on long- 
and short-term therapy at treatment initiation and planned 
follow-up visits allows patients’ opinions to be reviewed 
periodically and can help to start a discussion on how these 
feelings change over time. The use of electronic patient 
records capturing such information for future use might 
enhance this practice. For example, it may be possible to 
include a specific field for a patient’s comments at routine 
visits, possibly recorded using electronic tablets and standard-
ized questionnaires. Indeed, in Germany, an electronic patient 
management system, in which data are captured from many 
sources, has been implemented successfully and is currently 
being evaluated further.24 In addition, access to support net-
works (eg, the internet and call centers) can help to resolve 
queries and address concerns between clinic appointments. 
The medical team should provide consistent communication 
on the nature and purpose of DMD therapy, to prevent the 
patient from “losing faith” in the team.
Treatment reevaluation
For long-term therapies, it is important that treatment be 
evaluated regularly. The authors believe this should be done 
at least annually and the strategy revised depending on the 
patient’s status. Patients should be involved in treatment deci-
sions and empowered to select treatment, following discussion 
with their physician. Further discussion may be required to 
help patients understand issues such as the need for a second-
line therapy for aggressive disease. Different approaches may 
be required at different stages of the disease.
Patient–physician relationships  
and decision making
Patient–physician partnership
A good relationship between the patient and the healthcare 
team has the potential to improve adherence, and thus 
treatment outcomes. The observation that adherence rates 
tend to be higher in clinical trials than in clinical practice12 
suggests that frequent contact with the physician, nurse, 
or other healthcare professional can help to achieve good 
adherence. However, the psychological attitude of patients 
participating in clinical trials might also differ from that of 
patients being managed in routine care: the perception that 
they are receiving a “new” and therefore “better” treatment 
can have a potent placebo effect, which may be lost when 
the drug becomes “standard treatment.” The authors do not 
consider it possible to suggest an optimal frequency for 
patient–physician contact, as the frequency of visits should 
be tailored to the individual.
Table 2 Barriers to long-term adherence and potential solutions
Barrier Potential solutions
Treatment fatigue Educate patients on the implications 
of taking treatment breaks or stopping 
therapy 
Discussion forums to remotivate 
patients 





Nurse education on side-effect 
management 
Guidelines for the management of 
injection-site reactions 
Reinforcement of correct injection 
technique/need to rotate injection sites 
to avoid injection-site reactions
Depression Screening for depressive symptoms 
Treatment of depressive symptoms
Multiple sclerosis-related  
cognitive decline
Support mechanisms 
Regular education forums 
Reminders of treatment timing (eg, 
SMS alerts) 
Involvement of family/carer in 
treatment discussions
Abbreviation: SMS, short message service, ie, text message.
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Alternative communication methods, such as email, 
between patients and physicians are becoming increasingly 
popular. While increased patient–physician dialog is a posi-
tive step, electronic communications may be time consuming, 
and physicians’ responses may not achieve the same depth 
or completeness as a face-to-face consultation. In addition, 
there is also the potential for misinterpretation in such com-
munications. In the authors’ experience, patients often ask 
the same question several times, indicating that they may 
not fully understand the information that had been provided. 
Although over half of patients completing the MS Choices 
survey reported discussing aspects of their treatment other 
than side effects with their physician or nurse, the survey 
did not explore whether patients understood the information 
that they had been given. Clearly, to achieve a real benefit 
for each patient, strategies to improve patient–physician 
communication should be explored. Such strategies include 
asking patients how much they understood of what they had 
been told, the provision of information in different formats 
(eg, in direct discussions, leaflets, videos, internet), and 
ensuring simple terminology is used to avoid confusing or 
“intimidating” the patient.
Physicians and nurses should work hard to establish and 
maintain a good relationship with their patients. Id  eally, 
patients should feel that they are a partner in decisions 
regarding the management of their disease and are able to 
raise concerns and talk openly with their physician/nurse. On 
the other hand, it is also important that patients trust their 
physician to make decisions that are in their best interests. In 
the authors’ experience, patients are not always honest with 
their physicians regarding adherence to therapy: developing 
good relationships and trust between patients and physicians 
is essential so that patients feel that they can talk openly and 
honestly about their care, without fear of consequences.
Involvement of patients in the treatment  
decision-making process
Most physicians believed that patients should be involved 
in choosing their treatment, but only around a quarter of 
patients felt that they had discussed treatment options 
with their medical team and had been involved in the final 
treatment decision. Around half of patients followed their 
physician’s/nurse’s recommendation after discussing their 
treatment options with them. Interestingly, most patients 
were aware of the possible risks and benefits of their current 
MS treatment, and increasingly patients obtain information 
from other sources such as patient forums and the internet. 
In some cases, patients may ask for more information once 
they have started treatment so that they feel informed about, 
but are not involved in, treatment decisions. For young, 
newly diagnosed patients, structured group discussions to 
promote knowledge and self-management have been shown 
to have benefits.25
Considering the discrepancies that were seen between 
patient and physician responses in the MS Choices su  rvey, 
it is clearly important that patients are more aware of issues 
surrounding their treatment, irrespective of whether they 
want the physician alone to make decisions regarding 
their treatment. The extent of patient involvement in the 
decision-making process is likely to be heavily influenced 
by cultural differences, which could explain the regional 
differences seen. The proportion of patients who felt fully 
involved ranged from 20% in Spain to 75% in Canada. 
These differences highlighted in the MS Choices survey 
largely reflect the authors’ clinical experience (Table 3) and 
previous findings.26,27 Engaging the patient in treatment deci-
sions can be empowering and has the potential to improve 
adherence.
Role of the MS nurse in improving 
adherence
The MS Choices survey did not question MS nurses or 
explore the relationship between patients and their MS 
nurse. However, the authors believe that MS nurses play a 
vital role in the care of patients with MS and, through their 
interactions with patients, can help patients adhere to their 
treatment. It would be interesting to know whether nurses’ 
responses to the questions posed in the MS Choices survey 
would be more closely aligned with patient response than 
were those of physicians. In the authors experience, many 
patients are more comfortable discussing certain aspects of 
their disease and treatment, such as sexual and sphincter 
disturbances or side effects, with their MS nurses than with 
their physicians, preferring instead to talk to their physicians 
about treatment choices. This observation suggests that 
patients feel able to ask questions about their disease and 
treatment-related side effects with their MS nurses that they 
may not want to discuss with their physicians.
Discussions with a nurse tend to be more relaxed than 
those with a physician, and may avoid complicated medical 
terms that may intimidate or confuse the patient. Nurses may 
be more likely to translate medical terminology into terms 
that patients can understand easily, such as talking about how 
far a patient can walk, rather than using the term “Expanded 
Disability Status Scale score.” In some countries, nurses 
visit patients at home at the start of treatment. This provides 
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a more relaxed forum for discussion and aims to reduce 
anxiety that patients may feel from being in a clinical setting. 
That patients may view nurses differently from physicians 
can be exploited to the patient’s advantage. Regular nurse-
led reviews (eg, every 6 months) can provide reassurance, 
advice on managing side effects, and allow open discussion 
to reevaluate patient expectations and address concerns. 
However, the extent to which MS nurses are involved in 
routine patient care differs between countries; for example, 
patients in the United Kingdom have more contact with MS 
nurses than with physicians. A well-developed network of 
neurology nurses, regular nurse training, and workshops on 
key issues such as side effects and adherence are important 
to ensure that patients receive consistent information and 
standard of care. That patients have different relationships 
with different healthcare professionals highlights the impor-
tance of ensuring that patients have regular access to both 
nurses and physicians.
Psychological patient profiling
The MS Choices survey highlighted numerous differences 
both between patients and physicians and between patients 
from different regions. It is important to remember to treat 
patients as individuals: psychological profiling is a potentially 
powerful but little used tool that can help physicians to under-
stand the individual patient’s wants and needs. P  sychological 
patient profiling, although not widely used, allows the 
“c  ategorization” of patients based on considerations such as 
emotional state. Profiling can help to identify who should be 
started earlier or later on treatment, and can help to decide 
on the best approach to gain patients’ acceptance of their 
situation and to initiate discussions on treatment options. 
Profiling can also help to determine the extent to which a 
patient will want to be involved in treatment decisions and 
to predict who is more or less likely to adhere to treatment 
and an individual’s reasons for nonadherence.
To achieve the greatest benefit, profiling should involve 
a clinical psychologist and a neuropsychologist as part of a 
multidisciplinary team. Assessments should be conducted at 
specific milestones. At the minimum, these should be when 
informing the patient of the diagnosis (both before and after 
the diagnosis is given), when starting treatment (both before 
and after the decision on treatment has been made), and when 
problems arise (eg, following a relapse or when a patient 
wants to discontinue treatment).
Recommendations based on lessons  
from MS Choices
Based on the findings of the MS Choices survey, and personal 
clinical experience in various countries across Europe, the 
authors would like to propose some recommendations regard-
ing how to maximize adherence in clinical practice (Table 4). 
Crucially, strategies should be determined on an individual-
patient basis and after engaging the patient in decisions regard-
ing their treatment, as appropriate for the individual.
Table 4 Recommendations for maximizing patient adherence in 
clinical practice
•  Psychological profiling should be performed to determine patients’:
  •  Attitude to their disease
  •  Attitude to treatment and motivating factors
  •  Desire to be actively involved in treatment decisions
  •  Positive and negative perceptions of long- and short-term treatment
 •   Preferred communication methods
•  Physicians should be educated regarding:
  •  Issues that are important to patients
  •  Factors that form barriers to adherence
  •  The need to regularly reinforce the importance of good adherence
•  Patients need educating regarding the importance of good adherence
•  Regular and frequent discussions should take place to:
  •  Ensure patients’ concerns are addressed
  •  Continually motivate patients to stay on treatment
•  An interdisciplinary team approach should be employed
•  Patients should have regular access to their multiple sclerosis nurse
Table 3 Opinions on regional differences in patient’s attitudes to their involvement in the treatment decision-making process
Country General patient attitude Author
Spain Do not want to choose their treatment 
Prefer the physician to make the decision
C Oreja-Guevara
Germany Want to be included in discussions 
Many wish to decide for themselves
T Ziemssen
United Kingdom Willing to receive a large amount of information 
Want to be included in the discussions regarding choice, but often request direction  
and guidance from healthcare team to support them in making a decision; it differs  
between individuals
D Thomas
Italy Differs between patients with different psychological profiles, cultural attitudes,  
and socioeconomic status
A Lugaresi
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Conclusion
The MS Choices survey revealed differences between 
patients and physicians concerning several aspects of treat-
ment, notably in the factors leading to treatment breaks or 
discontinuations. Regional differences between countries 
were also identified, and which may reflect cultural and/or 
economic influences, which should be given due consid-
eration during patient consultations. The findings of the 
survey confirmed that treatment adherence is an important 
and complex issue in MS; here, barriers to adherence and 
potential approaches to improving adherence were dis-
cussed. For patients requiring chronic treatment, possibly 
over several decades, it is probably not realistic to expect 
them to achieve “total” adherence. A flexible, individualized 
approach may be more appropriate, to include authorized 
treatment breaks after careful consideration of potential 
risks. Psychological profiling can help to identify factors 
that are important to, and that will motivate, individual 
patients. A good relationship between patients and their 
medical team is essential. Patients should be involved in 
treatment decision making, should they so wish, and should 
have realistic expectations of therapy. Regular discussions 
should take place between patients and their physician or 
nurse, preferably both.
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